Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open Label First In Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor GRC 54276 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Pembrolizumab or Anti-PD-L1 Atezolizumab in Subjects With Advanced Solid Tumors and Lymphomas

Next Previous
Search
Trial Profile

A Phase 1, Open Label First In Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor GRC 54276 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Pembrolizumab or Anti-PD-L1 Atezolizumab in Subjects With Advanced Solid Tumors and Lymphomas

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Checkpoint kinase inhibitors (Primary) ; GRC 54276 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Colon cancer; Head and neck cancer; Hodgkin's disease; Lymphoma; Male breast cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Glenmark Pharmaceuticals S.A.

    • Most Recent Events

    • 22 Jul 2024 Status changed from recruiting to active, no longer recruiting.
    • 15 Jun 2023 Results (n=11) assessing safety and tolerability of GRC 54276 as a monotherapy and in combination with pembrolizumab or atezolizumab and to establish the Maximum Tolerated Dose (MTD) or Recommended Phase 2Dose (RP2D) as a single agent and in > combination therapy presented at the 28th Congress of the European Haematology Association
    • 29 May 2023 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top